| EVOTEC NEUROSCIENCES GMBH Patent applications |
| Patent application number | Title | Published |
|---|
| 20110053951 | METHODS FOR TREATING DISORDERS USING NMDA NR2B-SUBTYPE SELECTIVE ANTAGONIST - A method of treating, preventing or ameliorating a disease or condition by inhibiting NR2B subunit containing NMDA receptors using a compound according to formula (I) or a pharmaceutically acceptable salt thereof: | 03-03-2011 |
| 20110010780 | KCNN3 AS DIAGNOSTIC AND THERAPEUTIC TARGET FOR NEURODEGENERATIVE DISEASES - The present invention discloses a dysregulation of the KCNN3 gene and the protein products thereof in Alzheimer's disease patients and individuals being at risk of developing Alzheimer's disease. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the KCNN3 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 01-13-2011 |
| 20100261182 | PPM1E PROTEINS AND NUCLEIC ACIDS AS TARGETS FOR NEURODEGENERATIVE DISEASES | 10-14-2010 |
| 20100234359 | TREATMENT OF SLEEP DISORDERS - The use of 7-chloro-3-(5-dimethylaminomethyl-[1,2,4]oxadiazol-3-yl)-5methyl 4,5-dihydro-imidazol[1,5,-a][1,4]benzodiazepine-6-one or its pharmaceutically acceptable salt for treating various types of insomnia. | 09-16-2010 |
| 20100008921 | Diagnostic and Therapeutic Target Adarb2 Proteins for Neurodegenerative Diseases - The present invention discloses a dysregulation of the ADARB2 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the ADARB2 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 01-14-2010 |
| 20090255003 | Diagnostic and therapeutic target SLC39A11 proteins for neurodegenerative diseases - The present invention discloses a dysregulation of the SLC39A11 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A11 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 10-08-2009 |
| 20090133135 | Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases - The present invention discloses a dysregulation of the SLC39A12 gene and the protein products thereof in Alzheimer's disease patients. Based on this finding, the invention provides methods for diagnosing and prognosticating Alzheimer's disease in a subject, and for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating and preventing Alzheimer's disease and related neurodegenerative disorders using the SLC39A12 gene and its corresponding gene products. Screening methods for modulating agents of neurodegenerative diseases are also disclosed. | 05-21-2009 |
| 20080301821 | Diagnostic and Therapeutic use of a Plasma Membrane Atpase - The present invention provides a protein encoded by the ATP2B gene and discloses the differential expression of the gene coding for ATP2B proteins in specific brain regions of Alzheimer's disease patients. Based on this finding, the invention provides a method for diagnosing or prognosticating Alzheimer's disease in a subject, or for determining whether a subject is at increased risk of developing Alzheimer's disease. Furthermore, this invention provides therapeutic and prophylactic methods for treating or preventing Alzheimer's disease and related neurodegenerative disorders using the ATP2B gene and its corresponding gene products. A method of screening for modulating agents of neurodegenerative diseases is also disclosed. | 12-04-2008 |
